Roche Annual General Meeting 2018

Roche Annual General Meeting 2018

Roche Annual General Meeting 2018

The FINANCIAL -- Roche announced on March 13 that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM).

The 880 attending shareholders, representing 86,42% of the total of 160,000,000 shares, approved the Management Report, the Financial Statements and the Consolidated Financial Statements for 2017.

Christoph Franz was confirmed as Chairman of the Board of Directors with 99,89% of the votes, according to Roche.

"2017 was a good year for Roche. The launch of Ocrevus for people with multiple sclerosis and the approval of Hemlibra for the treatment of people with haemophilia A were outstanding. In particular, we made significant progress in the areas of personalised healthcare and digitization. In this field, we have entered into important partnerships that complement our own expertise. I believe Roche is very well prepared for the future," said Christoph Franz, Chairman of Roche's Board of Directors.

Shareholders also authorised the ratification of the Board of Directors' actions and approved an increase in the gross dividend for the past financial year to 8.30 Swiss francs (gross) per share and non-voting equity security. This is the 31st consecutive dividend increase.

Shareholders endorsed the total amount of bonuses paid to the Corporate Executive Committee for 2017 with 99,62% of the votes, as well as the bonus paid to the Chairman of the Board of Directors for 2017, which was approved by 99,51% of the votes. They also approved the maximum total amount of future remuneration of the Board of Directors, which was confirmed by 99,62% of the votes, and the maximum total amount of future remuneration for the Corporate Executive Committee until the 2019 ordinary Annual General Meeting by 99,64% of the votes.

In addition to Christoph Franz, all other Board members who stood for re-election were confirmed for a term of one year:

André Hoffmann
Professor Sir John Bell
Julie Brown
Paul Bulcke
Anita Hauser
Professor Dr Richard P. Lifton
Dr Andreas Oeri
Bernard Poussot
Dr Severin Schwan
Dr Claudia Süssmuth Dyckerhoff
Peter R. Voser

The following Board members were elected to the Remuneration Committee:

Dr Christoph Franz
André Hoffmann
Professor Dr Richard P. Lifton
Bernard Poussot
Peter R. Voser
KPMG AG was elected as external auditor for the financial year 2018 and BDO AG was elected as independent voting proxy until the conclusion of the next regular AGM in 2019.

 


Videos

Watch the video